Rong Zhou Sells 10,000 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total value of $239,400.00. Following the sale, the executive vice president owned 169,203 shares of the company’s stock, valued at $4,050,719.82. This represents a 5.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Wednesday, September 2nd, Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $23.63, for a total value of $75,308.81.

Amphastar Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ:AMPH opened at $23.62 on Friday. The stock has a 50-day simple moving average of $21.29 and a 200-day simple moving average of $20.35. The stock has a market capitalization of $1.00 billion, a P/E ratio of 13.98, a PEG ratio of 4.59 and a beta of 0.92. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $29.52. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $4,689,000. Dimensional Fund Advisors LP boosted its holdings in Amphastar Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after purchasing an additional 228,262 shares during the period. Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 2,864.4% during the fourth quarter. Pacer Advisors Inc. now owns 177,744 shares of the company’s stock valued at $4,760,000 after purchasing an additional 171,748 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth $3,286,000. Finally, Bank of America Corp DE acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth $2,761,000. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AMPH shares. Wells Fargo & Company boosted their price objective on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Bank of America reiterated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 12th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $22.50.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.